The University of Manchester: Rheumatoid arthritis (RA) affects about 0.8% of the adult population in the UK.

Data-sharing agreement from NHS Digital registers of approved data releases, 2014–2019. Evidence status: source reported.

Organisation

The University of Manchester

Source reference

DARS-NIC-147993-QY3ZL-v0.0

Jurisdiction

England

Licence

Open Government Licence v3.0, subject to NHS England terms and exclusions

Rheumatoid arthritis (RA) affects about 0.8% of the adult population in the UK. RA is also associated with increased and premature cardiovascular (CV) mortality. Almost half of all deaths in RA (and about 35 - 40% of the excess deaths) are due to cardiovascular disease (CVD). High levels of inflammation in RA sufferers can cause damage to blood vessels. Statins are drugs that can help to prevent diseases of the heart and blood vessels by reducing cholesterol and possibly inflammation. This trial will investigate whether the statin called Atorvastatin (Lipitor) can reduce the occurrence of cond

Register reference

DARS-NIC-147993-QY3ZL-v0.0

Agreement period

not published to no end date published

For commercial purposes (as marked in the register)

Not stated

Release files listed by NHS England

12

Data approved

• MRIS - Cause of Death Report
• MRIS - Cohort Event Notification Report
• MRIS - Scottish NHS / Registration

Objective, as published

Rheumatoid arthritis (RA) affects about 0.8% of the adult population in the UK. RA is also associated with increased and premature cardiovascular (CV) mortality. Almost half of all deaths in RA (and about 35 - 40% of the excess deaths) are due to cardiovascular disease (CVD). High levels of inflammation in RA sufferers can cause damage to blood vessels. Statins are drugs that can help to prevent diseases of the heart and blood vessels by reducing cholesterol and possibly inflammation. This trial will investigate whether the statin called Atorvastatin (Lipitor) can reduce the occurrence of conditions such as heart attack and stroke in patients with RA. The trial also aims to investigate whether Atorvastatin can reduce the level of inflammation in the joints in people who have significant RA disease activity at the time that they are included into the trial.

Source: https://webarchive.nationalarchives.gov.uk/ukgwa/2019/http://content.digital.nhs.uk/media/23861/Release-Register-December-16---February-17/xls/Release_Register__December_16_-_February_17.xlsx. Captured 2026-10-30.

Limitations: Agreement as recorded in an NHS Digital register of approved data releases (2014–2019), retrieved from the UK Government Web Archive. That register lists releases made in its period and the agreement's purpose statement as it then stood; it gives no agreement dates, and the agreement may have changed since. Imported only where a paper quotes a reference no current register holds.